Learn about Novo Nordisk and their contributions to the pharmaceutical industry. Find out how their innovative approach is improving the lives of millions of people worldwide.
Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of "phenomenal" performance by its new anti-obesity injection Saxenda, a senior company official said on Monday.
Novo Nordisk (NOVOb.CO) shares rose 3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not solely due to weight loss.